Tirzepatide vs Retatrutide

Overview

Tirzepatide is widely discussed through GIP and GLP-1 receptors. Retatrutide adds glucagon to that conversation.

The distinction is mechanistic—useful for study design, not compound ranking.

Differences

• Tirzepatide is commonly framed as a dual GIP and GLP-1 agonist.
• Retatrutide is commonly framed across GLP-1, GIP, and glucagon receptors.
• Neither page implies superiority, interchangeability, or clinical use.

Mechanism

Tirzepatide: GIP and GLP-1 receptor engagement is the central pharmacological description in metabolic literature.

Retatrutide: Glucagon co-agonism distinguishes its receptor narrative from dual incretin framing.

Pharmacology

Tirzepatide: Pharmacokinetic detail should be read from primary literature.

Retatrutide: Pharmacokinetic detail should be read from primary literature.

Research

Tirzepatide: Metabolic & GLP-1 research: Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Retatrutide: Metabolic & GLP-1 research: Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/41406444/
• pubmed.ncbi.nlm.nih.gov/38912654/
• pubmed.ncbi.nlm.nih.gov/37385275/
• pubmed.ncbi.nlm.nih.gov/39536238/
• pubmed.ncbi.nlm.nih.gov/35658024/
• pubmed.ncbi.nlm.nih.gov/40353578/
• pubmed.ncbi.nlm.nih.gov/34170647/
• pubmed.ncbi.nlm.nih.gov/39555826/

Questions